Strumberg D - Search Results

1

Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening.

Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ. Verstappen CC, et al. Among authors: strumberg d. Neurology. 2005 Mar 22;64(6):1076-7. doi: 10.1212/01.WNL.0000154642.45474.28. Neurology. 2005. PMID: 15781834 Clinical Trial.

2

Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.

Koeppen S, Verstappen CC, Körte R, Scheulen ME, Strumberg D, Postma TJ, Heimans JJ, Huijgens PC, Kiburg B, Renzing-Köhler K, Diener HC. Koeppen S, et al. Among authors: strumberg d. J Cancer Res Clin Oncol. 2004 Mar;130(3):153-60. doi: 10.1007/s00432-003-0524-9. Epub 2004 Jan 16. J Cancer Res Clin Oncol. 2004. PMID: 14727106 Clinical Trial.

3

Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer.

Strumberg D, Brügge S, Korn MW, Koeppen S, Ranft J, Scheiber G, Reiners C, Möckel C, Seeber S, Scheulen ME. Strumberg D, et al. Ann Oncol. 2002 Feb;13(2):229-36. doi: 10.1093/annonc/mdf058. Ann Oncol. 2002. PMID: 11885999 Free article.

4

The Ras-Raf-MEK-ERK pathway in the treatment of cancer.

Hilger RA, Scheulen ME, Strumberg D. Hilger RA, et al. Among authors: strumberg d. Onkologie. 2002 Dec;25(6):511-8. doi: 10.1159/000068621. Onkologie. 2002. PMID: 12566895 Review.

5

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.

Strumberg D, Schultheis B, Adamietz IA, Christensen O, Buechert M, Kraetzschmar J, Rajagopalan P, Ludwig M, Frost A, Steinbild S, Scheulen ME, Mross K. Strumberg D, et al. Br J Cancer. 2008 Nov 18;99(10):1579-85. doi: 10.1038/sj.bjc.6604724. Br J Cancer. 2008. PMID: 19002179 Free PMC article. Clinical Trial.

6

Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.

Hilger RA, Kredtke S, Scheulen ME, Seeber S, Strumberg D. Hilger RA, et al. Among authors: strumberg d. Int J Clin Pharmacol Ther. 2004 Nov;42(11):648-9. doi: 10.5414/cpp42648. Int J Clin Pharmacol Ther. 2004. PMID: 15598034 Clinical Trial. No abstract available.

7

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K. Strumberg D, et al. Br J Cancer. 2012 May 22;106(11):1722-7. doi: 10.1038/bjc.2012.153. Epub 2012 May 8. Br J Cancer. 2012. PMID: 22568966 Free PMC article. Clinical Trial.

8

Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.

Schmittel A, Scheulen ME, Bechrakis NE, Strumberg D, Baumgart J, Bornfeld N, Foerster MH, Thiel E, Keilholz U. Schmittel A, et al. Among authors: strumberg d. Melanoma Res. 2005 Jun;15(3):205-7. doi: 10.1097/00008390-200506000-00010. Melanoma Res. 2005. PMID: 15917703 Clinical Trial.

9

[Nutrition, lifestyle and cancer: strategies for primary prevention].

Strumberg D, Boeing H, Scheulen ME, Förster H, Seeber S. Strumberg D, et al. Dtsch Med Wochenschr. 2004 Sep 3;129(36):1877-82. doi: 10.1055/s-2004-831355. Dtsch Med Wochenschr. 2004. PMID: 15368163 Review. German. No abstract available.

10

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients.

Pieck AC, Drescher A, Wiesmann KG, Messerschmidt J, Weber G, Strumberg D, Hilger RA, Scheulen ME, Jaehde U. Pieck AC, et al. Among authors: strumberg d. Br J Cancer. 2008 Jun 17;98(12):1959-65. doi: 10.1038/sj.bjc.6604387. Epub 2008 May 27. Br J Cancer. 2008. PMID: 18506148 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

116 results

Search Page